In a stark revelation of bureaucratic inefficiency, a recent audit by the Department of Health and Human Services (HHS) Office of Inspector General (OIG) has uncovered that Medicare Part D has been hemorrhaging hundreds of millions of dollars on ineligible drug reimbursements. The audit exposes a systemic failure within the Centers for Medicare & Medicaid Services (CMS) to adequately screen for drugs that have transitioned from prescription-only status to over-the-counter (OTC) availability.
Between 2021 and 2023, the federal government inadvertently paid out $587.7 million for medications that were no longer legally eligible for Part D coverage. As the Medicare program faces mounting fiscal pressures and a looming insolvency date for its hospital insurance trust fund, these "improper payments" have sparked a firestorm of criticism regarding government oversight and the urgent need for structural reform in drug benefit administration.
The Scope of the Improper Payments
Medicare Part D is explicitly designed to cover prescription medications, not the consumer-grade OTC products that Americans can purchase off the shelf at any pharmacy. However, the OIG’s investigation confirms that the program’s current guardrails are failing to adapt to the changing market status of common pharmaceuticals.
The data reveals a consistent and concerning upward trend in these ineligible expenditures:
- 2021: $184 million
- 2022: $194.54 million
- 2023: $209.14 million
The primary culprit behind this fiscal drain is the generic equivalent of Voltaren, a topical nonsteroidal anti-inflammatory drug (NSAID) used extensively for arthritis management. Alone, this single class of medication accounted for $562.1 million of the total $587.7 million in improper reimbursements, having been prescribed approximately 15.8 million times during the audit period.
Beyond Voltaren, the OIG identified four other drug categories that contributed to the shortfall: generic versions of the eye drops Pataday and Lastacaft (used for ocular itching), the nasal spray Astepro (an antihistamine for allergy relief), and Sklice (a topical treatment for head lice). Each of these products successfully transitioned to OTC status, yet Medicare’s payment systems continued to treat them as reimbursable prescription items, effectively subsidizing consumer purchases that fall outside the program’s mandate.
Chronology of the Oversight Failure
The path to this multi-million dollar error is rooted in a disconnect between regulatory agencies and the operational realities of pharmacy benefit management.
2021: The Beginning of the Data Gap
At the start of the audit period, CMS relied on drug pricing and classification files that utilized outdated FDA data. Even as pharmaceutical companies successfully petitioned the FDA to switch the status of popular drugs from prescription to OTC, the CMS systems—which inform what Part D plans include in their formularies—remained stagnant.
2022: The Akorn Precedent
While the current OIG audit highlights the systemic failure of the CMS, the issue of "zombie" prescription labeling has surfaced in previous legal battles. In 2022, the Akorn Operating Company settled with the federal government for nearly $8 million. The manufacturer had continued to sell three generic drugs under obsolete prescription-only labeling despite the drugs having been cleared for OTC use. This case served as an early warning that manufacturers might be incentivized to maintain prescription branding even after an OTC switch to secure continued insurance coverage.
December 2024: Regulatory Action
The pressure finally culminated in a decisive policy shift from the FDA. In late 2024, the agency issued a mandate requiring generic drug manufacturers to update their labeling within six months of receiving approval for an OTC transition. While this is a critical step for consumer clarity, the OIG audit suggests that this measure is insufficient if CMS does not concurrently enforce a rejection of claims for these products.
Supporting Data: The Mechanics of the Leak
The OIG audit identified two specific "failure points" that allowed these payments to persist:
- Stale Formulary Data: The CMS periodically updates a file listing drug products that Part D plans can include in their coverage. Because this file was populated with outdated FDA status data, it essentially granted "pre-approval" to Part D sponsors to continue covering drugs that were legally no longer prescription-only.
- Lack of Rejection Timeframes: Even when a drug was identified as OTC, regulators failed to establish a standardized deadline by which Part D plans were required to stop processing claims. This ambiguity allowed plans to continue billing Medicare for millions of dollars in claims without fear of audit or rejection.
The sheer volume of prescriptions—nearly 16 million for the Voltaren generics alone—suggests that the issue is not limited to a few rogue pharmacies or providers, but is a systemic issue embedded in the automated billing systems that process millions of Medicare claims daily.
Official Responses and Path Forward
The OIG’s report was shared with both the FDA and the CMS prior to its public release. The FDA’s stance is clear: the onus is on the manufacturer to update labels, and the onus is on the payer to honor the new regulatory status.
CMS officials have officially concurred with the OIG’s recommendations. They have signaled an intent to issue formal guidance to Part D sponsors that aligns with the FDA’s new six-month labeling update policy. This guidance would theoretically force private prescription drug plans to automatically reject claims for any product that has crossed the threshold into OTC status.
However, a cloud of uncertainty remains. When pressed for a timeline on when this critical guidance will be released, CMS did not provide a specific date. Critics argue that without an immediate, aggressive rollout of these rules, the "leak" in the Medicare budget will continue to cost taxpayers millions each month.
Broader Implications for Medicare
The revelation of these improper payments arrives at a precarious time for the Medicare program.
The Insolvency Crisis
The Hospital Insurance (HI) trust fund is projected to run dry by 2033. The depletion of these funds has been accelerated by a combination of legislative tax cuts and the demographic reality of an aging population. Every dollar lost to improper reimbursements is a dollar that contributes to the long-term instability of the program, forcing policymakers to eventually choose between raising taxes, cutting benefits, or allowing the program to face a massive shortfall.
The Burden of Specialty and Chronic Care
Beyond the issue of OTC drugs, the program is struggling to contain the costs of a new generation of high-priced specialty medications. The widespread demand for GLP-1 agonists (weight loss and diabetes drugs) and the rising costs of managing a sicker, more complex patient population have pushed Part D spending to record highs. When the program fails to prevent spending on simple, low-cost drugs that should be OTC, it erodes public trust in the ability of the government to manage the much larger, more complex expenditures currently reshaping the American healthcare landscape.
A Focus on Fraud and Waste
The Trump administration has signaled an intensified focus on rooting out fraud, waste, and abuse (FWA). This audit provides a blueprint for what that crackdown might look like. By identifying specific, high-volume improper payments, the government is signaling that it will no longer tolerate the "passive" oversight that characterized the last several years. The pressure is now on the CMS to demonstrate that it can pivot from a passive administrator to an active, vigilant guardian of the Medicare trust fund.
Conclusion
The $587.7 million in improper payments is more than a clerical error; it is a symptom of a bloated and reactive regulatory environment. As the U.S. continues to navigate the complexities of modern drug pricing and an aging demographic, the ability of agencies like the CMS to keep pace with the market—specifically regarding the transition of drugs to OTC status—is essential. Whether the government can move from "concurring with recommendations" to actual implementation of robust, automated rejection systems will determine if the program can begin to plug its leaks and focus its limited resources on the truly necessary care that Medicare was designed to provide.
